1
|
Bakhta S, Sadaoui Z, Bouazizi N, Samir B, Cosme J, Allalou O, Le Derf F, Vieillard J. Successful removal of fluoride from aqueous environment using Al(OH) 3@AC: column studies and breakthrough curve modeling. RSC Adv 2024; 14:1-14. [PMID: 38173592 PMCID: PMC10758771 DOI: 10.1039/d3ra06697e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Accepted: 11/28/2023] [Indexed: 01/05/2024] Open
Abstract
In this study, we discuss the removal of fluoride from water through column adsorption methods using Al(OH)3@AC as a functional granular activated carbon. The height of the bed, fluoride concentration, and flow rate are the experimental factors used to obtain the breakthrough curves. As the flow rate increased, the breakthrough and saturation times decreased. The analysis of simplified column models, such as the Adams-Bohart, Thomas, and Yoon-Nelson models, revealed that the Clark model best described the adsorption process when fitting the experimental data. The obtained breakthrough curves agreed with the corresponding experimental data. The highest capacity for adsorption obtained during the column procedure was found to be 41.84 mg g-1 with a bed height of 3 cm, an initial fluoride concentration of 10 mg L-1 and a flow rate of 7.5 mL min-1.
Collapse
Affiliation(s)
- S Bakhta
- Laboratory of Reaction Engineering, Faculty of Mechanical and Processes Engineering, University of Sciences and Technology Houari-Boumediene BP No. 32, El Alia, Bab Ezzouar 16111 Algiers Algeria
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS COBRA (UMR 6014) 27000 Evreux France
| | - Z Sadaoui
- Laboratory of Reaction Engineering, Faculty of Mechanical and Processes Engineering, University of Sciences and Technology Houari-Boumediene BP No. 32, El Alia, Bab Ezzouar 16111 Algiers Algeria
| | - N Bouazizi
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS COBRA (UMR 6014) 27000 Evreux France
| | - B Samir
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS COBRA (UMR 6014) 27000 Evreux France
| | - J Cosme
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS COBRA (UMR 6014) 27000 Evreux France
| | - O Allalou
- Laboratory of Reaction Engineering, Faculty of Mechanical and Processes Engineering, University of Sciences and Technology Houari-Boumediene BP No. 32, El Alia, Bab Ezzouar 16111 Algiers Algeria
| | - F Le Derf
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS COBRA (UMR 6014) 27000 Evreux France
| | - J Vieillard
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS COBRA (UMR 6014) 27000 Evreux France
| |
Collapse
|
2
|
Silva MIT, Cosme J, Lorenzo C, Virtuoso J, Gomes R, Pedro E, Neves AM, Lopes A. Hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs on a pediatric Portuguese cohort. Eur Ann Allergy Clin Immunol 2023. [PMID: 37249059 DOI: 10.23822/eurannaci.1764-1489.299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Summary Background. Non-steroidal anti-inflammatory drugs (NSAID)/analgesics (paracetamol) are among the most common causes of drug hypersensitivity reactions in children, with a reported prevalence of around 0.3% in the pediatric population. Paracetamol and ibuprofen are the most commonly reported culprits in the pediatric population. Our objective was to describe the allergy workup to NSAID/paracetamol of a pediatric population monitored in an allergy outpatient clinic. Methods. Retrospective observational study by consulting the medical records of patients evaluated in a pediatric outpatient clinic with history of NSAID/paracetamol, between January 2016 to August 2022. Results. A total of 43 patients have been evaluated for NSAID/paracetamol suspected allergy: 53.5% females, mean age of 9.8 ± 5.1 years, 47.7% atopic. The drugs reported as culprits were: ibuprofen (75.6%), paracetamol (17.8%), metamizole (4.4%) and naproxen (2.2%) and clinical manifestations were mainly urticaria/angioedema and maculopapular exanthema. Skin tests were performed in 7 patients: paracetamol (n = 5) and metamizole (n = 2), which were all negative. Fourty-six drug provocation tests were performed: 28 with the culprit drug and 18 with an alternative one; only 2 were positive (ibuprofen - culprit NSAID group): one immediate periorbital angioedema and one delayed lip edema with oropharyngeal tightness. Conclusions. The investigation of allergy to NSAID/paracetamol in children remains a challenge. In our population, ibuprofen was the most common NSAID reported. There were only 2 (4.3%) mild reactions on DPT. We could allow the use of the culprit NSAID/analgesic in 11 patients and an alternative one in 9 patients. This study highlights the importance of DPT in children for a correct diagnosis of NSAID hypersensitivity and selection of an alternative drug.
Collapse
Affiliation(s)
- M I T Silva
- Department of Immunoallergology, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| | - J Cosme
- Department of Immunoallergology, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| | - C Lorenzo
- Department of Pediatric, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| | - J Virtuoso
- Department of Pediatric, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
- Department of Pediatric, Unidade Local de Saúde da Guarda, Hospital Sousa Martins, Guarda, Portugal
| | - R Gomes
- Department of Pediatric, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| | - E Pedro
- Department of Immunoallergology, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| | - A M Neves
- Department of Pediatric, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| | - A Lopes
- Department of Immunoallergology, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| |
Collapse
|
3
|
Esteves Caldeira L, Silva MIT, Pedro E, Cosme J. Hypersensitivity to Vespa velutina nigrithorax: an emerging problem in Portugal? Eur Ann Allergy Clin Immunol 2023. [PMID: 36633159 DOI: 10.23822/eurannaci.1764-1489.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- L Esteves Caldeira
- Immunoallergology Service, Centro Hospitalar Universitário Lisboa Norte (CHULN), EPE, Lisbon, Portugal
| | - M I T Silva
- Immunoallergology Service, Centro Hospitalar Universitário Lisboa Norte (CHULN), EPE, Lisbon, Portugal
| | - E Pedro
- Immunoallergology Service, Centro Hospitalar Universitário Lisboa Norte (CHULN), EPE, Lisbon, Portugal
| | - J Cosme
- Immunoallergology Service, Centro Hospitalar Universitário Lisboa Norte (CHULN), EPE, Lisbon, Portugal
| |
Collapse
|
4
|
Varandas C, Esteves Caldeira L, Silva SL, Costa C, Limão R, Silva MI, Lopes A, Caiado J, Cosme J, Alonso E, Marcelino J, Cabral Duarte F, Fernandes NP, Neto M, Pedro E, Branco Ferreira M, Spínola Santos A. Hereditary angioedema: 24 years of experience in a Portuguese Reference Center. Eur Ann Allergy Clin Immunol 2022. [PMID: 36515257 DOI: 10.23822/eurannaci.1764-1489.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Summary Hereditary angioedema (HAE) poses a high burden of disease, being its epidemiological and clinical data heterogeneous among countries, with no recent published studies concerning Portuguese patients. Therefore, we aimed to raise awareness of HAE and to contribute to clinical knowledge. An observational, descriptive, retrospective, and cross-sectional study was performed, that included a cohort of 126 patients followed in a single Portuguese Center. We observed a high prevalence of HAE-C1-INH type II (45.2% of patients). Most HAE patients (67.4%) presented the initial manifestations of the disease before adulthood, at a mean age of 12.6 ± 8.4 years. However, we found a long delay in HAE diagnosis, especially in those without family history (mean 20.7 ± 17.3 years). Stress was the most common trigger, followed by trauma and infection. Symptoms involving different systems were increasingly reported with increased disease duration. Cutaneous symptoms (95.0%) were more frequent, followed by gastrointestinal (80.7%), and respiratory symptoms (50.4%). HAE symptoms led to abdominal surgery in 22 (17.5%) patients and induced laryngeal edema requiring intubation/tracheostomy in 8 (6.3%) patients. Most patients were under long-term prophylaxis, mainly with attenuated androgens (62.7% of patients).The correct distinction between HAE and other common causes of angioedema is critical, allowing reduction of diagnostic delay, improvement of adequate management, and ultimately improving outcomes and quality of life of HAE patients.
Collapse
Affiliation(s)
- C Varandas
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - L Esteves Caldeira
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - S L Silva
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
- Immunoallergology University Clinic, Faculty of Medicine, Lisbon University, Lisbon, Portugal
| | - C Costa
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
- Immunoallergology University Clinic, Faculty of Medicine, Lisbon University, Lisbon, Portugal
| | - R Limão
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - M I Silva
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - A Lopes
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
- Immunoallergology University Clinic, Faculty of Medicine, Lisbon University, Lisbon, Portugal
| | - J Caiado
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
- Immunoallergology University Clinic, Faculty of Medicine, Lisbon University, Lisbon, Portugal
| | - J Cosme
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
- Immunoallergology University Clinic, Faculty of Medicine, Lisbon University, Lisbon, Portugal
| | - E Alonso
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - J Marcelino
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - F Cabral Duarte
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - N P Fernandes
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - M Neto
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - E Pedro
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
| | - M Branco Ferreira
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
- Immunoallergology University Clinic, Faculty of Medicine, Lisbon University, Lisbon, Portugal
| | - A Spínola Santos
- Department of Immunoallergology, Santa Maria Hospital, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Lisboa, Lisbon, Portugal
- Immunoallergology University Clinic, Faculty of Medicine, Lisbon University, Lisbon, Portugal
| |
Collapse
|
5
|
Limão R, Spínola Santos A, Araújo L, Cosme J, Inácio F, Tomaz E, Ferrão A, Santos N, Sokolova A, Môrete A, Falcão H, Cunha L, Ferreira A, Bras A, Ribeiro F, Lozoya C, Leiria Pinto P, Prates S, Plácido J, Coimbra A, Taborda-Barata L, Pereira Santos MC, Pereira Barbosa M, Pineda F. Molecular Sensitization Profile to Dermatophagoides pteronyssinus Dust Mite in Portugal. J Investig Allergol Clin Immunol 2020; 32:33-39. [PMID: 32732183 DOI: 10.18176/jiaci.0533] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
OBJECTIVE To analyze component resolved diagnosis to Dermatophagoides pteronyssinus (Der p) in patients with respiratory allergy and its relationship with clinical severity in different geographical areas. METHODS 217 patients (mean age 25.85±12.7 years; 51.16% females) were included, selected from 13 centers in Portugal (5 from North, n=65). All had allergic rhinitis, with or without asthma, and had positive skin prick tests to at least one dust mite. Specific IgE (sIgE) to Der p, Dermatophagoides farinae, Lepidoglyphus destructor, Der p1, Der p 2, Der p 10 and Der p 23 were determined by ImmunoCAP. Statistical analysis (Mann Whitney U test) compared patients with rhinitis vs rhinitis and asthma; mild vsmoderate-to-severe rhinitis; North vs South. RESULTS Prevalence of sensitization was 98.2% to Der p, and 72.4%, 89.4%, 9.7% and 77% to Der p 1, Der p 2, Der p 10 and Der p 23, respectively. Corresponding median sIgE levelswere 8.56, 17.7, 0.01 and 3.95 kUA/L. sIgE to all allergens was higher in patients with moderate-to-severe rhinitis and rhinitis with asthma but not statistically significant (NSS). sIgE to Der p 2 was significantly higher in the South when compared with the North (p=0.0496). CONCLUSIONS sensitization to Der p is the most common in Portugal. Der p 2 had the highest prevalence and median sIgE levels. All sIgE to molecular components were higher in more symptomatic patients (NSS). sIgE to Der p 2 was higher in the South, which may be related to the warmer temperature and/or the larger sample size.
Collapse
Affiliation(s)
- R Limão
- Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Portugal.,Allergen and Immunotherapy Interest Group, Sociedade Portuguesa de Alergologia e Imunologia Clínica, Portugal
| | - A Spínola Santos
- Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Portugal.,Allergen and Immunotherapy Interest Group, Sociedade Portuguesa de Alergologia e Imunologia Clínica, Portugal
| | - L Araújo
- Allergen and Immunotherapy Interest Group, Sociedade Portuguesa de Alergologia e Imunologia Clínica, Portugal.,Immunoallergology Department, Faculdade de Medicina da Universidade do Porto, Portugal
| | - J Cosme
- Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Portugal.,Allergen and Immunotherapy Interest Group, Sociedade Portuguesa de Alergologia e Imunologia Clínica, Portugal
| | - F Inácio
- Allergen and Immunotherapy Interest Group, Sociedade Portuguesa de Alergologia e Imunologia Clínica, Portugal.,Immunoallergology Department, Hospital de São Bernardo, Setúbal, Portugal
| | - E Tomaz
- Immunoallergology Department, Hospital de São Bernardo, Setúbal, Portugal
| | - A Ferrão
- Immunoallergology Unit, Hospital do Espírito Santo de Évora, Portugal
| | - N Santos
- Immunoallergology Unit, Hospital de Portimão, Centro Hospitalar Universitário do Algarve, Portugal
| | - A Sokolova
- Allergen and Immunotherapy Interest Group, Sociedade Portuguesa de Alergologia e Imunologia Clínica, Portugal.,Immunoallergology Unit, Hospital Professor Doutor Fernando Fonseca, Amadora-Sintra, Portugal
| | - A Môrete
- Immunoallergology Unit, Hospital de Aveiro, Centro Hospitalar Baixo Vouga, Portugal
| | - H Falcão
- Immunoallergology Department, Hospital de Santo António, Centro Hospitalar do Porto, Portugal
| | - L Cunha
- Immunoallergology Department, Hospital de Santo António, Centro Hospitalar do Porto, Portugal
| | - A Ferreira
- Immunoallergology Unit, Hospital das Forças Armadas, Lisboa, Portugal
| | - A Bras
- Immunoallergology Unit, Hospital de Faro, Centro Hospitalar Universitário do Algarve, Portugal
| | - F Ribeiro
- Immunoallergology Unit, Hospital de Faro, Centro Hospitalar Universitário do Algarve, Portugal
| | - C Lozoya
- Immunoallergology Unit, Unidade Local de Saúde de Castelo Branco, Portugal
| | - P Leiria Pinto
- Immunoallergology Department, Hospital Dona Estefânia, Centro Hospitalar Universitário de Lisboa Central, Portugal
| | - S Prates
- Immunoallergology Department, Hospital Dona Estefânia, Centro Hospitalar Universitário de Lisboa Central, Portugal
| | - J Plácido
- Immunoallergology Department, Centro Hospitalar Universitário de São João, Porto, Portugal
| | - A Coimbra
- Immunoallergology Department, Centro Hospitalar Universitário de São João, Porto, Portugal
| | - L Taborda-Barata
- Immunoallergology Department, Centro Hospitalar Universitário Cova da Beira, Covilhã, Portugal
| | - M C Pereira Santos
- Allergen and Immunotherapy Interest Group, Sociedade Portuguesa de Alergologia e Imunologia Clínica, Portugal.,Clinical Immunology Laboratory, Faculdade de Medicina, Instituto de Medicina Molecular, Universidade de Lisboa, Portugal
| | - M Pereira Barbosa
- Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Portugal.,Clinical Immunology Laboratory, Faculdade de Medicina, Instituto de Medicina Molecular, Universidade de Lisboa, Portugal.,University Clinic of Immunoallergology, Faculdade de Medicina da Universidade de Lisboa, Portugal
| | - F Pineda
- Diater Laboratorio de Diagnostico y Aplicaciones Terapeuticas SA, Madrid, Spain
| |
Collapse
|
6
|
Constant C, Cosme J, Fernandes RM, Fonte P, Fonseca JA, Alves C, Bandeira T. Practice of spirometry among physicians caring for children with asthma in Portugal - The EspiroPed survey. Pulmonology 2019; 26:54-56. [PMID: 31562046 DOI: 10.1016/j.pulmoe.2019.07.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2018] [Revised: 05/17/2019] [Accepted: 07/22/2019] [Indexed: 10/26/2022] Open
Affiliation(s)
- C Constant
- Unidade de Pneumologia Pediátrica, Departamento de Pediatria, Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte, Centro Académico de Medicina de Lisboa.
| | - J Cosme
- Serviço de Imunoalergologia, Hospital de Santa Maria, CHLN EPE, Portugal
| | - R M Fernandes
- Unidade de Alergologia Pediátrica, Departamento de Pediatria, Hospital de Santa Maria, CHLN EPE, Centro Académico de Medicina de Lisboa, Lisboa, Portugal
| | - P Fonte
- Unidade de Saúde Familiar do Minho, ACeS Cávado I - Braga, Escola de Medicina/Instituto de Investigação em Ciências da Vida e Saúde, Universidade do Minho, Grupo de Estudos de Doenças Respiratórias, Associação Portuguesa de Medicina Geral e Familiar, Portugal
| | - J A Fonseca
- Imunoalergologia, CUF Porto Hospital e Instituto, CINTESIS, Faculdade de Medicina da Universidade do Porto, Sociedade Portuguesa de Alergologia e Imunologia Clínica, Portugal
| | - C Alves
- Serviço de Pneumologia, Hospital Nossa Senhora do Rosário, Centro Hospitalar Barreiro-Montijo, Sociedade Portuguesa de Pneumologia, Portugal
| | - T Bandeira
- Unidade de Pneumologia Pediátrica, Departamento de Pediatria, Hospital de Santa Maria, Centro Hospitalar de Lisboa Norte, Centro Académico de Medicina de Lisboa, Sociedade Portuguesa de Pediatria, Portugal
| |
Collapse
|
7
|
Cosme J, Spínola-Santos A, Bartolomé B, Pastor-Vargas C, Branco-Ferreira M, Pereira-Santos MC, Pereira-Barbosa M. Salmon Roe as an Emerging Allergen in Western Countries. J Investig Allergol Clin Immunol 2019; 29:139-141. [PMID: 31017113 DOI: 10.18176/jiaci.0347] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J Cosme
- Serviço de Imunoalergologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
| | - A Spínola-Santos
- Serviço de Imunoalergologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
| | | | - C Pastor-Vargas
- Department of Immunology, Instituto de Investigación Sanitaria Hospital, Universitario Fundación Jiménez Díaz. (IIS-FJD, UAM), Madrid, Spain. RETIC ARADyAL, Instituto de Salud Carlos III, Spain
| | - M Branco-Ferreira
- Serviço de Imunoalergologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal.,Clínica Universitária de Imunoalergologia, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| | - M C Pereira-Santos
- Clínica Universitária de Imunoalergologia, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.,Laboratório de Imunologia Clínica, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| | - M Pereira-Barbosa
- Serviço de Imunoalergologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal.,Clínica Universitária de Imunoalergologia, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| |
Collapse
|
8
|
Cosme J, Spínola-Santos A, Pereira-Santos MC, Pereira-Barbosa M. Venom Immunotherapy: a 20-year experience with an ultra-rush protocol (210-min). Eur Ann Allergy Clin Immunol 2019; 51:122-128. [PMID: 30702236 DOI: 10.23822/eurannaci.1764-1489.85] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
SUMMARY Background. Ultra-rush (UR) are induction protocols used in venom immunotherapy (VIT). Objectives: To evaluate the adverse reactions during a 210-minutes UR and determine possible risk factors. Methods: Retrospective study of 129 patients submitted to UR with VIT in the last 20 years. Results: In 114 (88.4%) patients the 101.1 μg maintenance dose was reached in 210 minutes. Systemic reactions (SR) occurred in 22% of patients (71% mild). There were no severe SR, late reactions or fatalities. Adrenaline was administered in 10% of all UR. The SR were more frequent with honey bee VIT and had greater severity in the patients with a previous severe systemic sting reaction. No significant difference in the risk of SR was found with other demographic, clinical or laboratory factors. There were 5% of large local reactions (LLR), these being more frequent in females. Conclusion: Most SR during UR were mild with no need for adrenaline treatment. The honey bee venom and the severity of the anaphylaxis during the field sting were the only SR´s risk factors for systemic adverse reactions during the UR.
Collapse
Affiliation(s)
- J Cosme
- Serviço de Imunoalergologia, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte (CHULN), Lisboa, Portugal
| | - A Spínola-Santos
- Serviço de Imunoalergologia, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte (CHULN), Lisboa, Portugal
| | - M C Pereira-Santos
- Laboratório de Imunologia Clínica, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
- Clínica Universitária de Imunoalergologia, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| | - M Pereira-Barbosa
- Serviço de Imunoalergologia, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte (CHULN), Lisboa, Portugal
- Clínica Universitária de Imunoalergologia, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| |
Collapse
|
9
|
Cosme J, Ignatchenko V, Principe S, Liu P, Kislinger T, Gramolini A. 365 Proteomic Characterization of the Cardiac Fibroblast Exosome. Can J Cardiol 2012. [DOI: 10.1016/j.cjca.2012.07.343] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
10
|
Williams PA, Cosme J, Vinkovic DM, Ward A, Angove H, Day P, Jhoti H. Structural biology of cytochromes P450. Acta Crystallogr A 2005. [DOI: 10.1107/s0108767305097187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
11
|
Matak-Vinkovic D, Williams PA, Cosme J, Ward A, Day P, Tickle IJ, Jhoti H. Crystal structures of human cytochrome P450 2C9 and 3A4 with bound ligands. Acta Crystallogr A 2004. [DOI: 10.1107/s0108767304097247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
12
|
Sechenykh AA, Dubanov AV, Skvortsov VS, Ivanov AS, Archakov AI, Williams P, Cosme J, Johnson EF, McRee DE. [Computer model of 3D structure of cytochrome P450 2B4]. Vopr Med Khim 2002; 48:526-38. [PMID: 12498097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
Cytochromes P450 (CYPs) play an important role in the oxidative metabolism of xenobiotics. Three-dimensional structures of CYPs are needed to study structure-function relationships in their molecules and interaction with partner proteins. Experimental determination of eucaryotic CYPs 3D structures is difficult because of hydrophobic membrane anchors and surface hydrophobic regions that prevent their crystallization. Replacement of surface hydrophobic amino acids by hydrophilic residues without any changes in protein structure and function can help to solve this problem. Such modification can be proposed using the analysis of 3D model of protein. In this work computer aided 3D structure of microsomal P450 2B4 (CYP2B4) was modeled for the further prediction of surface mutations for hydrophilization of the protein surface. The model of 3D structure of CYP2B4 was constructed by homology with CYP2C5 Model optimization was made by energy minimization and molecular dynamics simulation of protein molecule in water environment. The model was verified by using special statistic software and by comparison with the experimental data on the substrate recognition site, redox-partner binding sites and chemical modification of the protein surface.
Collapse
Affiliation(s)
- A A Sechenykh
- Orekhovich Institute of Biomedical Chemistry RAMS, 10, Pogodinskaya str., Moscow, 119121, Russia
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
Although microsomal P450s represent the majority of P450s, only microbial P450s have been amenable to crystal structure solution. We have recently solved the first crystal structure of a microsomal P450, 2C5, a progesterone hydroxylase from rabbit. We discuss the features of the protein in common with existing structures of microbial P450s and limitations of homology modeling mammalian P450s based on the microbial structures. Unique features involving membrane, substrate and cytochrome P450 reductase interactions are also discussed.
Collapse
Affiliation(s)
- P A Williams
- Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | | | | | | | | |
Collapse
|
14
|
Cosme J, Johnson EF. Engineering microsomal cytochrome P450 2C5 to be a soluble, monomeric enzyme. Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding. J Biol Chem 2000; 275:2545-53. [PMID: 10644712 DOI: 10.1074/jbc.275.4.2545] [Citation(s) in RCA: 141] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Deletion of the N-terminal membrane-spanning domain from microsomal P450s 2C5 and 2C3 generates the enzymes, 2C5dH and 2C3dH, that exhibit a salt-dependent association with membranes indicating that they retain a monofacial membrane interaction domain. The two proteins are tetramers and dimers, respectively, in high salt buffers, and only 2C5dH requires phospholipids to reconstitute fully the catalytic activity of the enzyme. Amino acid residues derived from P450 2C3dH between residues 201 and 210 were substituted for the corresponding residues in P450 2C5 to identify those that would diminish the membrane interaction, the phospholipid dependence of catalysis, and aggregation of 2C5dH. Each of four substitutions, N202H, I207L, S209G, and S210T, diminished the aggregation of P450 2C5dH and produced a monomeric enzyme. The N202H and I207L mutations also diminished the stimulation of catalytic activity by phospholipid and reduced the binding of P450 2C5dH to phospholipid vesicles. The modified enzymes exhibit rates of progesterone 21-hydroxylation that are similar to that of P450 2C5dH. These conditionally membrane-bound P450s with improved solubility in high salt buffers are suitable for crystallization and structural determination by x-ray diffraction studies.
Collapse
Affiliation(s)
- J Cosme
- Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
| | | |
Collapse
|
15
|
Williams PA, Cosme J, Sridhar V, Johnson EF, McRee DE. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 2000; 5:121-31. [PMID: 10678174 DOI: 10.1016/s1097-2765(00)80408-6] [Citation(s) in RCA: 534] [Impact Index Per Article: 22.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Microsomal cytochrome P450s participate in xenobiotic detoxification, procarcinogen activation, and steroid hormone synthesis. The first structure of a mammalian microsomal P450 suggests that the association of P450s with the endoplasmic reticulum involves a hydrophobic surface of the protein formed by noncontiguous portions of the polypeptide chain. This interaction places the entrance of the putative substrate access channel in or near the membrane and orients the face of the protein proximal to the heme cofactor perpendicular to the plane of the membrane for interaction with the P450 reductase. This structure offers a template for modeling other mammalian P450s and should aid drug discovery and the prediction of drug-drug interactions.
Collapse
Affiliation(s)
- P A Williams
- Department of Molecular Biology MB-8, Scripps Research Institute, La Jolla, California 92037, USA
| | | | | | | | | |
Collapse
|
16
|
Halpert JR, Domanski TL, Adali O, Biagini CP, Cosme J, Dierks EA, Johnson EF, Jones JP, Ortiz de Montellano P, Philpot RM, Sibbesen O, Wyatt WK, Zheng Z. Structure-function of cytochromes P450 and flavin-containing monooxygenases: implications for drug metabolism. Drug Metab Dispos 1998; 26:1223-31. [PMID: 9860932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023] Open
Abstract
This article is a report on a symposium held at Experimental Biology '98 in San Francisco, California. Recent developments in site-directed mutagenesis, computer-modeling, and mechanistic analysis of cytochromes P450 and flavin-containing monooxygenases are described. A unifying theme is the elaboration of general approaches for understanding and predicting the function of individual forms of these enzymes. A related goal is the production of soluble forms of mammalian cytochromes P450 for X-ray crystallography.
Collapse
Affiliation(s)
- J R Halpert
- Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Legrand-Andréoletti M, Stücker I, Marez D, Galais P, Cosme J, Sabbagh N, Spire C, Cenée S, Lafitte JJ, Beaune P, Broly F. Cytochrome P450 CYP2D6 gene polymorphism and lung cancer susceptibility in Caucasians. Pharmacogenetics 1998; 8:7-14. [PMID: 9511176 DOI: 10.1097/00008571-199802000-00002] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Many studies have been performed in an attempt to establish a link between the polymorphism of the cytochrome P450 CYP2D6 gene and the incidence of lung cancer. Nevertheless, whether or not this genetic polymorphism has a role in the development of the disease remains unclear. Recently, new advances in our knowledge of the CYP2D6 gene and its locus (CYP2D) have been achieved. In particular, CYP2D6 was found to be highly polymorphic and multiple novel mutations and allelic variants of the gene have been identified. In addition, a number of CYP2D rearrangements, including those with amplification of the gene, have been demonstrated. Taking this new information into account, we have reconsidered the potential influence of CYP2D6 polymorphism in lung cancer susceptibility by performing a comparative analysis of the overall mutational spectrum of CYP2D6 and of the rearrangements of CYP2D in 249 patients with lung cancer and in 265 control individuals matched on age, sex, hospital and residence area. For this purpose, a strategy based on SSCP analysis of the entire coding sequence of CYP2D6 and on RFLP analysis of the gene locus was carried out in DNA samples from each individual. Forty mutations occurring in various combinations on 42 alleles of the gene and 82 different genotypes were identified. No significant difference in the distribution of the mutations, alleles or genotypes was observed between the two groups, except a particular genotype (CYP2D6*1A/*2), which was more common in the sub-group of moderate smokers (< 30 pack-years) suffering from small cell carcinoma (Odds Ratio (OR) 3.6, 95% CI 1.1-11.9). When the phenotype was predicted according to genotype, only a trend toward a higher frequency of ultrarapid metabolizers in patients was obtained. In spite of a complete analysis of the CYP2D6 gene and its locus, this case-control study provides elements against an influence of the CYP2D6 polymorphism on lung cancer susceptibility.
Collapse
|
18
|
Guengerich FP, Parikh A, Johnson EF, Richardson TH, von Wachenfeldt C, Cosme J, Jung F, Strassburg CP, Manns MP, Tukey RH, Pritchard M, Fournel-Gigleux S, Burchell B. Heterologous expression of human drug-metabolizing enzymes. Drug Metab Dispos 1997; 25:1234-41. [PMID: 9351898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
This article is a report on a symposium held at the March 1997 meeting of the American Society for Pharmacology and Experimental Therapeutics in San Diego. Current developments in the heterologous expression of cytochrome P450, NADPH-cytochrome P450 reductase, glutathione transferase, and UDP-glucuronosyltransferase enzymes are described. Systems include bacteria, insect cells, and transient and stable mammalian cells. Uses of the products are described for discernment of which enzymes are involved in metabolism of drugs, genotoxicity assays, mutagenesis (for structure-activity relationships), large scale production of enzyme products, antibody production, and production of proteins for biophysical studies.
Collapse
Affiliation(s)
- F P Guengerich
- Department of Biochemistry and Center in Molecular Toxicology, Vanderbilt University School of Medicine
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
von Wachenfeldt C, Richardson TH, Cosme J, Johnson EF. Microsomal P450 2C3 is expressed as a soluble dimer in Escherichia coli following modification of its N-terminus. Arch Biochem Biophys 1997; 339:107-14. [PMID: 9056240 DOI: 10.1006/abbi.1996.9859] [Citation(s) in RCA: 91] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
A hydrophobic segment present in the N-terminus of microsomal P450s is thought to serve as a membrane anchor. A variant of P450 2C3 was constructed, P450 2C3d, that lacked the putative membrane-spanning segment of the N-terminus, residues 3-20. This construct also incorporated substitutions of an alanine for 2Asp to facilitate expression in Escherichia coli and of serines for 24His and 25Gly to introduce a restriction site. P450 2C3d is expressed at relatively high levels in E. coli, 800-1200 nmol/liter of culture medium. In contrast to P450 2C3mod, which retains a membrane-spanning N-terminal sequence modified for expression in E. coli, the subcellular distribution of P450 2C3d in E. coli is dependent on the ionic strength of the buffer used for cell disruption. In low ionic strength buffers, 2C3d was mainly localized in the membrane fraction, whereas in buffers containing 1 M NaCl or 0.5 M KPi, P450 2C3d was predominantly found in the soluble fraction, indicating that deletion of the hydrophobic segment converted the intrinsic membrane protein to an extrinsic one. P450 2C3d was further modified by the incorporation of four histidine residues at the C-terminus (P450 2C3dH), and this enzyme could be purified in the absence of detergent using immobilized metal affinity chromatography following extraction from isolated membranes in high salt buffers. The catalytic properties of the purified, modified enzymes are similar to those of the native enzyme. Size-exclusion chromatography indicated that 2C3dH and 2C3d are predominantly dimers, whereas 2C3 is a larger oligomer (> 8-mer). Moreover, the detergents sodium cholate and Chaps each dissociate the dimers of 2C3dH to monomers at concentrations that do not alter the aggregation state of 2C3. These modifications are likely to facilitate attempts to crystallize the catalytic domains of microsomal P450s.
Collapse
Affiliation(s)
- C von Wachenfeldt
- Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, California 92037, USA
| | | | | | | |
Collapse
|
20
|
Gautier JC, Lecoeur S, Cosme J, Perret A, Urban P, Beaune P, Pompon D. Contribution of human cytochrome P450 to benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol metabolism, as predicted from heterologous expression in yeast. Pharmacogenetics 1996; 6:489-99. [PMID: 9014198 DOI: 10.1097/00008571-199612000-00002] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The metabolism of benzo[a]pyrene (B[a]P) and its proximate mutagen B[a]P-7,8-dihydrodiol (7,8-diol) was investigated in the presence of human microsomal epoxide hydrolase and P450 1A1, 1A2, 2C8, 2C9, 2C18, 2C19, 2D6 and 3A4 expressed in the yeast Saccharomyces cerevisiae. P450 1A1 had the highest turnover numbers for the formation of all B[a]P metabolites, including phenols and dihydrodiols. P450 1A2, 2C8, 2C9, 2C18, 2C19 and 3A4, which are well represented in the liver, gave rise to the formation of appreciable amounts of 3-hydroxy-B[a]P and of some dihydrodiols from B[a]P. When 7,8-diol was used as substrate, P450 1A1 also exhibited the highest turnover numbers for the formation of tetrols, the hydrolysis products of the diolepoxides, whereas P450 1A2, 2C8, 2C19 and 3A4 showed moderate activities. In order to test the validity of the yeast system, the contribution of each P450 isoform to B[a]P and 7,8-diol metabolism was evaluated as the product of the turnover numbers of recombinant P450s by specific contents of each P450 in human liver microsomes. Calculated formation rates for each B[a]P and 7,8-diol metabolite globally matched experimental values. There is evidence that P450 3A4 and 2C9 play a major role in the formation of 3-hydroxy-B[a]P from B[a]P. Accumulation of the proximate mutagen 7,8-diol was predicted to be mainly driven by P450 1A2, 2C9 and 2C19, while formation of the genotoxic diolepoxides from 7,8-diol appeared to be dependent on P450 1A2 and 3A4 in the liver.
Collapse
Affiliation(s)
- J C Gautier
- Inserm U75, Université René Descartes, Faculté de médecine Necker-Enfants-Malades, Paris, France
| | | | | | | | | | | | | |
Collapse
|
21
|
Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 1996; 59:613-23. [PMID: 8681486 DOI: 10.1016/s0009-9236(96)90001-6] [Citation(s) in RCA: 125] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
BACKGROUND AND OBJECTIVE Antipyrine has been widely used as a probe drug for human oxidative drug metabolism. To evaluate the role of antipyrine as a model drug, we have identified the cytochrome P450 enzymes involved in 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. METHODS We used the following methods for this study: (1) determination of enzyme kinetics for antipyrine metabolite formation in human liver microsomes, (2) inhibition studies with antibodies and inhibitors, and (3) formation of metabolites by stable expressed human P450 enzymes. RESULTS Antipyrine biotransformation could be described by Michaelis-Menten kinetics: norantipyrine: maximum rate of metabolite formation (Vmax), 0.91 +/- 0.04 nmol . mg-1 . min-1; Michaelis-Menten constant (Km), 19.0 +/- 0.8 mmol/L; 4-hydroxyantipyrine: Vmax, 1.54 +/- 0.08 nmol . mg-1 . min-1;Km,39.6 +/- 2.5 mmol/L. Antibodies against CYP3A4 inhibited the formation of 4-hydroxyantipyrine by 25% to 65%. LKM-2 antibodies (anti-CYP2C) caused a 75% to 100% inhibition of norantipyrine and a 58% to 80% inhibition of 3-hydroxymethylantipyrine formation. Sulfaphenazole inhibited the formation of 3-hydroxymethylantipyrine and norantipyrine by about 50%. Furafylline and fluvoxamine inhibited norantipyrine, 4-hydroxyantipyrine, and 3-hydroxymethylantipyrine formation by about 30%, 30%, and 50%, respectively. Ketoconazole reduced formation of norantipyrine, 3-hydroxymethylantipyrine, and 4-hydroxyantipyrine by up to 80%. Formation in stable expressed enzymes indicated involvement of CYP1A2, CYP2B6, CYP2C, and CYP3A4 in metabolite formation. CONCLUSION Antipyrine metabolites are formed by at least six hepatic cytochrome P450 enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C18, and CYP3A4). 4-Hydroxylation is mainly catalyzed by CYP3A4 and, to a lesser extent, by CYP1A2. The CYP2C subfamily contains the predominant enzymes for norantipyrine formation, and CYP1A2 is also involved. Formation of 3-hydroxymethylantipyrine is mediated by CYP1A2 and CYP2C9. Because several cytochrome P450 enzymes are involved in the formation of each metabolite, antipyrine is not well suited as a probe for distinct human cytochrome P450 enzymes.
Collapse
Affiliation(s)
- G Engel
- Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, Germany
| | | | | | | | | |
Collapse
|
22
|
Belloc C, Baird S, Cosme J, Lecoeur S, Gautier JC, Challine D, de Waziers I, Flinois JP, Beaune PH. Human cytochromes P450 expressed in Escherichia coli: production of specific antibodies. Toxicology 1996; 106:207-19. [PMID: 8571393 DOI: 10.1016/0300-483x(95)03178-i] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Cytochromes P450 (CYP) constitute a superfamily of enzymes involved in the metabolism of xenobiotics. Within the same subfamily, the isoforms present strong similarities, making them difficult to characterize and differentiate. Using heterologous expression in bacteria, five pure human CYP (1A1, 1A2, 2C9, 2E1, 3A4) were easily obtained and used as antigens to raise specific antibodies. These antibodies were characterized for their specificity and sensitivity by immunoblots; anti-CYP3A4 was immunoinhibitor. These antibodies could be used in association with other means to identify the CYPs responsible for production of a given metabolite. The use of our human recombinant CYP1A2 as antigen and the corresponding specific antibody enabled us to quantify the CYP1A2 content in 43 human livers. The average level was 69 pmol of CYP1A2/mg of microsomal proteins. Finally, these antibodies were also used to evaluate the level of heme incorporation in human microsomal CYP expressed in yeasts.
Collapse
Affiliation(s)
- C Belloc
- Institut National de la Santé et de la Recherche Médicale Unité 75, Université René Descartes, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Soucek P, Guo Z, Sandhu P, Martin MV, Cosme J, Beaune PH, Guengerich FP. Identification of the highly polymorphic S-mephenytoin hydroxylase in humans. Arch Toxicol Suppl 1996; 18:437. [PMID: 8678819 DOI: 10.1007/978-3-642-61105-6_40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- P Soucek
- National Institute of Public Health, Center of Occupational Diseases, Prague, Czech Republic
| | | | | | | | | | | | | |
Collapse
|
24
|
Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1995; 353:116-21. [PMID: 8750925 DOI: 10.1007/bf00168924] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The calcium channel blocker verapamil [2,8-bis-(3,4-dimethoxyphenyl)-6-methyl-2-isopropyl-6-azaoctanitrile+ ++] undergoes extensive biotransformation in man. We have previously demonstrated cytochrome P450 (CYP) 3A4 and 1A2 to be the enzymes responsible for verapamil N-dealkylation (formation of D-617 [2-(3,4-dimethoxyphenyl)-5-methylamino-2-isopropylvaleronitrile], and verapamil N-demethylation (formation of norverapamil [2,8-bis-(3,4-dimethoxyphenyl)-2-isopropyl-6-azaoctanitrile]), while there was no involvement of CYP3A4 and CYP1A2 in the third initial metabolic step of verapamil, which is verapamil O-demethylation. This pathway yields formation of D-703 [2-(4-hydroxy-3-methoxyphenyl)-8-(3,4-dimethoxyphenyl)-6-methyl-2-isopro pyl-6-azaoctanitrile] and D-702 [2-(3,4-dimethoxyphenyl)-8-(4-hydroxy-3-methoxyphenyl)-6-methyl-2-isopro pyl-6-azaoctanitrile]. The enzymes catalyzing verapamil O-demethylation have not been characterized so far. We have therefore identified and characterized the enzymes involved in verapamil O-demethylation in humans by using the following in vitro approaches: (I) characterization of O-demethylation kinetics in the presence of the microsomal fraction of human liver, (II) inhibition of verapamil O-demethylation by specific antibodies and selective inhibitors and (III) investigation of metabolite formation in microsomes obtained from yeast strain Saccharomyces cerevisiae W(R), that was genetically engineered for stable expression of human CYP2C8, 2C9 and 2C18. In human liver microsomes (n=4), the intrinsic clearance (CLint), as derived from the ratio of Vmax/Km, was significantly higher for O-demethylation to D-703 compared to formation of D-702 following incubation with racemic verapamil (13.9 +/- 1.0 vs 2.4 +/- 0.6 ml*min-1*g-1, mean+/-SD; p<0.05), S-verapamil (16.8 +/- 3.3 vs 2.2 +/- 1.2 ml* min-1*g-1, p<0.05) and R-verapamil (12.1 +/- 2.9 vs 3.6 +/- 1.3 ml*min-1*g-1; p<0.05), thus indicating regioselectivity of verapamil O-demethylation process. The CLint of D-703 formation in human liver microsomes showed a modest but significant degree of stereoselectivity (p<0.05) with a S/R-ratio of 1.41 +/- 0.17. Anti-LKM2 (anti-liver/kidney microsome) autoantibodies (which inhibit CYP2C9 and 2C19) and sulfaphenazole (a specific CYP2C9 inhibitor) reduced the maximum rate of formation of D-703 by 81.5 +/- 4.5% and 45%, that of D-702 by 52.7 +/- 7.5% and 72.5%, respectively. Both D-703 and D-702 were formed by stably expressed CYP2C9 and CYP2C18, whereas incubation with CYP2C8 selectively yielded D-703. In conclusion, our results show that enzymes of the CYP2C subfamily are mainly involved in verapamil O-demethylation. Verapamil therefore has the potential to interact with other drugs which inhibit or induce these enzymes.
Collapse
Affiliation(s)
- D Busse
- Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart, Germany
| | | | | | | | | |
Collapse
|
25
|
Stücker I, Cosme J, Laurent P, Cenée S, Beaune P, Bignon J, Depierre A, Milleron B, Hémon D. CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure. Carcinogenesis 1995; 16:2759-64. [PMID: 7586196 DOI: 10.1093/carcin/16.11.2759] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Polymorphism for CYP2D6 was determined genetically as part of a hospital-based case-control study. The cases were males with a histologically confirmed lung cancer diagnosis, < 75 years old, and no previous cancer diagnosis. Male controls were matched for age, hospital and residence area. This study includes 301 cases and 310 controls. A DNA bank was established for 547 patients (89.5%), and genotypes for CYP2D6 were differentiated by the Heim and Meyer method for the DNA samples of 249 cases and 271 controls. Among the cases, the frequencies of homozygous for the wild-type (EM), heterozygous (HEM) and homozygous for the mutant alleles (PM) were 62%, 32% and 7%; among the controls: 57%, 37% and 6%. Using EM as the reference, and adjusting for age, hospital and residence, we estimated the odds ratios for the HEM group and the PM group at 0.8 (95% CI [0.5-1.2]) and 1.1 (95% CI [0.5-2.4]) respectively. The PM frequency among the cases of adenocarcinoma was twice as high as among the controls (OR = 1.8, 95% CI [0.7-4.9]). This result was not observed among squamous and small cell carcinoma (OR = 0.7, 95% CI [0.3-1.8]). Twelve different case-control studies on CYP2D6 and lung cancer have so far been performed; the ORs they estimate range from 0.1 to 2.0, with a median value of approximately 0.6. This result lends some support to the hypothesis that belonging to the PM group is associated with a slight protective effect against lung cancer, but does not take into account the possibility that results may vary according to histologic type. In this context, the suggestion of a positive relationship between CYP2D6 and adenocarcinoma seems to us to merit investigation.
Collapse
Affiliation(s)
- I Stücker
- Unité de Recherches Epidémiologiques et Statistiques sur l'Environnement et la Santé, INSERM U 170, Villejiuf, France
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich FP, Maurel P. Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 1995; 47:410-8. [PMID: 7870052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
The aim of this work was to identify the form(s) of human cytochrome P450 (P450) involved in the hepatic biotransformation of lansoprazole to its two main metabolites, i.e., the sulfone and the hydroxy derivative. In liver microsomes, the production of the sulfone of lansoprazole correlated with the level of P450 3A4, cyclosporin oxidase, and the production of the hydroxy derivative, as well as of omeprazole sulfone. The production of hydroxylansoprazole moderately correlated with the level of P450 3A4, cyclosporin oxidase, and (S)-mephenytoin 4'-hydroxylase. The production of the sulfone and of the hydroxy derivative of lansoprazole was significantly inhibited by anti-P450 3A4 antibodies, by cyclosporin and ketoconazole, and by tolbutamide. Anti-P450 2C8 and 2C3 antibodies moderately inhibited the biotransformation of lansoprazole, whereas they completely inhibited (S)-mephenytoin 4'-hydroxylase activity under the same conditions. In primary cultures of human hepatocytes, the biotransformation of lansoprazole and the oxidation of cyclosporin were strongly increased by rifampicin and phenobarbital, whereas (S)-mephenytoin 4'-hydroxylation was not. beta-Naphthoflavone did not induce the formation of the sulfones but stimulated the production of hydroxylansoprazole. Among several forms of cDNA-expressed human P450s, 3A4 generated significant amounts of the sulfones of lansoprazole and omeprazole and 2C18 was active for the production of hydroxylansoprazole but inactive in the 4'-hydroxylation of (S)-mephenytoin. We conclude that P450 3A4 is the major enzyme involved in the production of the sulfone of lansoprazole and that this P450, as well as P450 2C18 and/or another 2C-related form, could contribute to the production of hydroxylansoprazole.
Collapse
Affiliation(s)
- L Pichard
- INSERM U-128, CNRS, Montpellier, France
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
le Roy D, Expert D, Razafindratsita A, Deroussent A, Cosme J, Bohuon C, Andremont A. Activity and specificity of a mouse monoclonal antibody to ferric aerobactin. Infect Immun 1992; 60:768-72. [PMID: 1541550 PMCID: PMC257552 DOI: 10.1128/iai.60.3.768-772.1992] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
We isolated a monoclonal antibody directed against the ferric complex of aerobactin purified from Escherichia coli KH576. This antibody, which we designated MAb AERO1, was identified as an immunoglobulin G, subtype 2. A competitive enzyme-linked immunosorbent assay with MAb AERO1 had a limit of 10 nM for the detection of purified ferric aerobactin and allowed detection of the crude aerobactin produced by various members of the family Enterobacteriaceae isolated from cancer patients with bacteremia. The only two other structurally related siderophores recognized by MAb AERO1 were ferric arthrobactin and ferrioxamine B. These results suggest that the epitope recognized by MAb AERO1 was the lysyl moiety of ferric aerobactin. We also showed that MAb AERO1 reduced the growth of an aerobactin-producing strain of E. coli in newborn calf serum, which indicates that it might be effective in reducing the severity of infections caused by bacteria for which the production of aerobactin is an important virulence factor.
Collapse
Affiliation(s)
- D le Roy
- Laboratoire d'Ecologie Microbienne, Institut Gustave-Roussy, Villejuif, France
| | | | | | | | | | | | | |
Collapse
|